Implications of Bcl-2 and its interplay with other molecules and signaling pathways in prostate cancer progression

References

• Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27.
   Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34–45.
   PubMed Web of Science ®Google Scholar
• Maughan BL, Antonarakis ES. Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin Pharmacother. 2015;16:1521–1537.
   PubMed Web of Science ®Google Scholar
• Assikis VJ, Simons JW. Novel therapeutic strategies for androgen-independent prostate cancer: an update. Semin Oncol. 2004;31:26–32.
   PubMed Web of Science ®Google Scholar
• Hockenbery D, Nunez G, Milliman C, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;348:334–336.
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984;226:1097–1099.
   PubMed Web of Science ®Google Scholar
• Ohigashi T, Ueno M, Nonaka S, et al. Bcl-2 and androgen receptor gene expression in androgen-independent subclone derived from mouse androgen-dependent cells. Cancer Invest. 2002;20:730–736.
   PubMed Web of Science ®Google Scholar
• McDonnell TJ, Navone NM, Troncoso P, et al. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol. 1997;157:569–574.
   PubMed Web of Science ®Google Scholar
• Furuya Y, Krajewski S, Epstein JI, et al. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res. 1996;2:389–398.
   PubMed Web of Science ®Google Scholar
• Gleave ME, Miayake H, Goldie J, et al. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urology. 1999;54:36–46.
   PubMed Web of Science ®Google Scholar
• Lin Y, Fukuchi J, Hiipakka RA, et al. Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage. Cell Res. 2007;17:531–536.
   PubMed Web of Science ®Google Scholar
• Miayake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst. 2000;92:34–41.
   PubMedGoogle Scholar
• Karnak D, Xu L. Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr Drug Targets. 2010;11(6):699–707.
   Web of Science ®Google Scholar
• Leung S, Miyake H, Zellweger T, et al. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int J Cancer. 2001;91:846–850.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Pradhan A, Das SK, et al. Novel therapy of prostate cancer employing a combination of viral-based immunotherapy and a small molecule BH3 mimetic. Oncoimmunology. 2016;5:e1078059.
   PubMed Web of Science ®Google Scholar
• Aragon-Ching JB, Dahut WL. Chemotherapy in androgen-independent prostate cancer (AIPC): what’s next after taxane progression? Cancer Ther. 2007;5A:151–160.
   PubMedGoogle Scholar
• Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 2009;15:1126–1132.
   PubMed Web of Science ®Google Scholar
• R D. Navitoclax and abiraterone acetate with or without hydroxychloroquine in treating patients with progressive metastatic castrate refractory prostate cancer. Clinicaltrialsgov: NCT01828476. 2013
   Google Scholar
• Sonpavde G, Matveev V, Burke JM, et al. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol. 2011;23:1803–1808.
   PubMed Web of Science ®Google Scholar
• Yoshino T, Shiina H, Urakami S, et al. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res. 2006;12:6116–6124.
   PubMed Web of Science ®Google Scholar
• Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440–442.
   PubMed Web of Science ®Google Scholar
• Lithgow T, Van Driel R, Bertram JF, et al. The protein product of the oncogene bcl-2 is a component of the nuclear envelope, the endoplasmic reticulum, and the outer mitochondrial membrane. Cell Growth Differ. 1994;5:411–417.
   PubMedGoogle Scholar
• Verma YK, Gangenahalli GU, Singh VK, et al. Cell death regulation by B-cell lymphoma protein. Apoptosis. 2006;11:459–471.
   PubMed Web of Science ®Google Scholar
• Kurinna S, Konopleva M, Palla SL, et al. Bcl2 phosphorylation and active PKC alpha are associated with poor survival in AML. Leukemia. 2006;20:1316–1319.
   PubMed Web of Science ®Google Scholar
• Perez-Galan P, Roue G, Lopez-Guerra M, et al. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia. 2008;22:1712–1720.
   PubMed Web of Science ®Google Scholar
• Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci U S A. 1995;92:4507–4511.
   PubMed Web of Science ®Google Scholar
• Czabotar PE, Lessene G, Strasser A, et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15:49–63.
   PubMed Web of Science ®Google Scholar
• Kahn B, Collazo J, Kyprianou N. Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer. Int J Biol Sci. 2014;10:588–595.
   PubMed Web of Science ®Google Scholar
• Green SM, Mostaghel EA, Nelson PS. Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol. 2012;360:3–13.
   PubMed Web of Science ®Google Scholar
• Bonkhoff H, Fixemer T, Remberger K. Relation between Bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer. Prostate. 1998;34:251–258.
   PubMed Web of Science ®Google Scholar
• Schweizer MT, Plymate SR. Targeting constitutively active androgen receptor splice variants in castration resistant prostate cancer. Expert Opin Ther Targets. 2016;20:903–906.
   PubMed Web of Science ®Google Scholar
• Raffo AJ, Perlman H, Chen MW, et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 1995;55:4438–4445.
   PubMed Web of Science ®Google Scholar
• Xu J, Qiu Y. Role of androgen receptor splice variants in prostate cancer metastasis. Asian J Urol. 2016;3:177–184.
   PubMed Web of Science ®Google Scholar
• Harris WP, Mostaghel EA, Nelson PS, et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clinical Practice Urol. 2009;6:76–85.
   PubMedGoogle Scholar
• Hughes IA, Werner R, Bunch T, et al. Androgen insensitivity syndrome. Semin Reprod Med. 2012;30:432–442.
   PubMed Web of Science ®Google Scholar
• Culig Z, Hoffmann J, Erdel M, et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer. 1999;81:242–251.
   PubMed Web of Science ®Google Scholar
• Hobisch A, Hoffmann J, Lambrinidis L, et al. Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model. Urol Int. 2000;65:73–79.
   PubMed Web of Science ®Google Scholar
• Huang H, Zegarra-Moro OL, Benson D, et al. Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells. Oncogene. 2004;23:2161–2176.
   PubMed Web of Science ®Google Scholar
• Parrondo R, de Las Pozas A, Reiner T, et al. ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells. PeerJ. 2013;1:e144.
   PubMed Web of Science ®Google Scholar
• Nemes A, Tomuleasa C, Kacso G. The androgen receptor remains a key player in metastatic hormone-refractory prostate cancer. Implications for new treatments. J Buon. 2014;19:357–364.
   PubMed Web of Science ®Google Scholar
• Ishikura N, Kawata H, Nishimoto A, et al. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10. Prostate. 2010;70:457–466.
   PubMed Web of Science ®Google Scholar
• Deng Q, Tang DG. Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications. Endocr Relat Cancer. 2015;22:T209–T220.
   PubMed Web of Science ®Google Scholar
• Marques RB, Dits NF, Erkens-Schulze S, et al. Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PloS One. 2010;5:e13500.
   PubMed Web of Science ®Google Scholar
• Klaassen Z, Howard LE, de Hoedt A, et al. Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer. Cancer. 2017;123:1528–1535.
   PubMed Web of Science ®Google Scholar
• So A, Chin J, Fleshner N, et al. Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: incorporating new agents into clinical practice. Can Urol Assoc J. 2012;6:465–470.
   PubMed Web of Science ®Google Scholar
• El-Amm J, Aragon-Ching JB. Targeting bone metastases in metastatic castration-resistant prostate cancer. Clin Med Insights Oncol. 2016;10(Suppl 1):11–19.
   Web of Science ®Google Scholar
• Qian G, Hao S, Yang D, et al. P15, MDM2, NF-kappaB, and Bcl-2 expression in primary bone tumor and correlation with tumor formation and metastasis. Int J Clin Exp Pathol. 2015;8:14885–14892.
   PubMed Web of Science ®Google Scholar
• Gomez-Veiga F, Ponce-Reixa J, Martinez-Breijo S, et al. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition. Actas Urol Esp. 2013;37:292–304.
   PubMed Web of Science ®Google Scholar
• Hammerich KH, Donahue TF, Rosner IL, et al. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer. Urol Oncol. 2017;35:460.e21-460.e28.
   PubMed Web of Science ®Google Scholar
• Migliaccio A, Castoria G, Di Domenico M, et al. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. Embo J. 2000;19:5406–5417.
   PubMed Web of Science ®Google Scholar
• Lee LF, Louie MC, Desai SJ, et al. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene. 2004;23:2197–2205.
   PubMed Web of Science ®Google Scholar
• Nakazawa M, Paller C, Kyprianou N. Mechanisms of therapeutic resistance in prostate cancer. Curr Oncol Rep. 2017;19:13.
   PubMed Web of Science ®Google Scholar
• Saad F. Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int. 2009;103:434–440.
   PubMed Web of Science ®Google Scholar
• Dong JT, Sipe TW, Hyytinen ER, et al. PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene. 1998;17:1979–1982.
   PubMed Web of Science ®Google Scholar
• Carnero A, Blanco-Aparicio C, Renner O, et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 2008;8:187–198.
   PubMed Web of Science ®Google Scholar
• Conley-LaComb MK, Saliganan A, Kandagatla P, et al. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling. Mol Cancer. 2013;12:85.
   PubMed Web of Science ®Google Scholar
• Nan B, Snabboon T, Unni E, et al. The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. J Mol Endocrinol. 2003;31:169–183.
   PubMed Web of Science ®Google Scholar
• Catz SD, Johnson JL. BCL-2 in prostate cancer: a minireview. Apoptosis. 2003;8:29–37.
   PubMed Web of Science ®Google Scholar
• Peacock JW, Palmer J, Fink D, et al. PTEN loss promotes mitochondrially dependent type II Fas-induced apoptosis via PEA-15. Mol Cell Biol. 2009;29:1222–1234.
   PubMed Web of Science ®Google Scholar
• Huang H, Cheville JC, Pan Y, et al. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem. 2001;276:38830–38836.
   PubMed Web of Science ®Google Scholar
• Calastretti A, Gatti G, Quaresmini C, et al. Down-modulation of Bcl-2 sensitizes PTEN-mutated prostate cancer cells to starvation and taxanes. Prostate. 2014;74:1411–1422.
   PubMed Web of Science ®Google Scholar
• Rosser CJ, Tanaka M, Pisters LL, et al. Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation. Cancer Gene Ther. 2004;11:273–279.
   PubMed Web of Science ®Google Scholar
• Deng X, Gao F, Flagg T, et al. Bcl2’s flexible loop domain regulates p53 binding and survival. Mol Cell Biol. 2006;26:4421–4434.
   PubMed Web of Science ®Google Scholar
• Ringer L, Sirajuddin P, Tricoli L, et al. The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells. Oncotarget. 2014;5:10678–10691.
   PubMed Web of Science ®Google Scholar
• Huang K, Tang Y, He L, et al. MicroRNA-340 inhibits prostate cancer cell proliferation and metastasis by targeting the MDM2-p53 pathway. Oncol Rep. 2016;35:887–895.
   PubMed Web of Science ®Google Scholar
• Silvestrini R, Veneroni S, Daidone MG, et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1994;86:499–504.
   PubMed Web of Science ®Google Scholar
• Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995;82:241–250.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li T, Yu X, et al. The RTK/ERK pathway is associated with prostate cancer risk on the SNP level: a pooled analysis of 41 sets of data from case-control studies. Gene. 2014;534:286–297.
   PubMed Web of Science ®Google Scholar
• Rubenstein M, Hollowell CM, Guinan P. Additional compensatory mechanisms altering antisense oligonucleotide suppression of BCL2: effects upon AKT1 and STAT3. In Vivo. 2014;28:867–870.
   PubMed Web of Science ®Google Scholar
• Rubenstein M, Hollowell CM, Guinan P. Suppression of BCL2 by antisense oligonucleotides and compensation by non-targeted genes may enhance tumor proliferation. In Vivo. 2015;29:687–693. [Research Support, Non-U.S. Gov’t].
   PubMed Web of Science ®Google Scholar
• Rubenstein M, Hollowell CM, Guinan P. In LNCaP cells enhanced expression of both androgen receptor and costimulatory protein p300 compensate for antisense oligonucleotide suppression of bcl-2. Ther Adv Urol. 2011;3:243–250.
   PubMedGoogle Scholar
• Zhang D, He D, Xue Y, et al. PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway. Cancer Res. 2011;71:2193–2202.
   PubMed Web of Science ®Google Scholar
• You L, Wang Z, Li H, et al. The role of STAT3 in autophagy. Autophagy. 2015;11:729–739.
   PubMed Web of Science ®Google Scholar
• Real PJ, Sierra A, De Juan A, et al. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene. 2002;21:7611–7618.
   PubMed Web of Science ®Google Scholar
• Nielsen M, Kaestel CG, Eriksen KW, et al. Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia. 1999;13:735–738.
   PubMed Web of Science ®Google Scholar
• Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 2008;18:254–267.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Dass JF. Study of pathway cross-talk interactions with NF-kappaB leading to its activation via ubiquitination or phosphorylation: a brief review. Gene. 2016;584:97–109.
   PubMed Web of Science ®Google Scholar
• Malinowska K, Neuwirt H, Cavarretta IT, et al. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer. 2009;16:155–169.
   PubMed Web of Science ®Google Scholar
• Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene. 2001;20:7342–7351.
   PubMed Web of Science ®Google Scholar
• Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell. 1996;87:629–638.
   PubMed Web of Science ®Google Scholar
• Ravi RK, McMahon M, Yangang Z, et al. Raf-1-induced cell cycle arrest in LNCaP human prostate cancer cells. J Cell Biochem. 1999;72:458–469.
   PubMed Web of Science ®Google Scholar
• De Chiara G, Marcocci ME, Torcia M, et al. Bcl-2 Phosphorylation by p38 MAPK: identification of target sites and biologic consequences. J Biol Chem. 2006;281:21353–21361.
   PubMed Web of Science ®Google Scholar
• Chaudhary P, Vishwanatha JK. c-Jun NH2-terminal kinase-induced proteasomal degradation of c-FLIPL/S and Bcl2 sensitize prostate cancer cells to Fas- and mitochondria-mediated apoptosis by tetrandrine. Biochem Pharmacol. 2014;91:457–473.
   PubMed Web of Science ®Google Scholar
• Zelivianski S, Spellman M, Kellerman M, et al. ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer. 2003;107:478–485.
   PubMed Web of Science ®Google Scholar
• Shin JA, Kim LH, Lee SJ, et al. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer. Oncotarget. 2015;6:35667–35683.
   PubMed Web of Science ®Google Scholar
• Guo JY, White E. Autophagy, Metabolism, and Cancer. Cold Spring Harb Symp Quant Biol. 2017;81:73–78.
   Google Scholar
• Liang XH, Kleeman LK, Jiang HH, et al. Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein. J Virol. 1998;72:8586–8596.
   PubMed Web of Science ®Google Scholar
• Marquez RT, Xu L. Bcl-2:beclin 1 complex: multiple, mechanisms regulating autophagy/apoptosis toggle switch. Am J Cancer Res. 2012;2:214–221.
   PubMed Web of Science ®Google Scholar
• Oberstein A, Jeffrey PD, Shi Y. Crystal structure of the Bcl-XL-Beclin 1 peptide complex: beclin 1 is a novel BH3-only protein. J Biol Chem. 2007;282:13123–13132.
   PubMed Web of Science ®Google Scholar
• Ciechomska IA, Goemans GC, Skepper JN, et al. Bcl-2 complexed with Beclin-1 maintains full anti-apoptotic function. Oncogene. 2009;28:2128–2141.
   PubMed Web of Science ®Google Scholar
• Lian J, Karnak D, Xu L. The Bcl-2-Beclin 1 interaction in (-)-gossypol-induced autophagy versus apoptosis in prostate cancer cells. Autophagy. 2010;6:1201–1203.
   PubMed Web of Science ®Google Scholar
• Lian J, Wu X, He F, et al. A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum. Cell Death Differ. 2011;18:60–71.
   PubMed Web of Science ®Google Scholar
• Rah B, Ur Rasool R, Nayak D, et al. PAWR-mediated suppression of BCL2 promotes switching of 3-azido withaferin A (3-AWA)-induced autophagy to apoptosis in prostate cancer cells. Autophagy. 2015;11:314–331.
   PubMed Web of Science ®Google Scholar
• Di Rita A, Strappazzon F. AMBRA1, a novel BH3-like protein: new insights into the AMBRA1-BCL2-family proteins relationship. Int Rev Cell Mol Biol. 2017;330:85–113.
   PubMedGoogle Scholar
• Strappazzon F, Di Rita A, Cianfanelli V, et al. Prosurvival AMBRA1 turns into a proapoptotic BH3-like protein during mitochondrial apoptosis. Autophagy. 2016;12:963–975.
   PubMed Web of Science ®Google Scholar
• Falasca L, Torino F, Marconi M, et al. AMBRA1 and SQSTM1 expression pattern in prostate cancer. Apoptosis. 2015;20:1577–1586.
   PubMed Web of Science ®Google Scholar
• Cho WC. MicroRNAs in cancer - from research to therapy. Biochim Biophys Acta. 2010;1805:209–217.
   PubMed Web of Science ®Google Scholar
• Altarejos JY, Montminy M. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol. 2011;12:141–151.
   PubMed Web of Science ®Google Scholar
• Ji Q, Hao X, Zhang M, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One. 2009;4:e6816.
   PubMed Web of Science ®Google Scholar
• Cheng CY, Hwang CI, Corney DC, et al. miR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment. Cell Rep. 2014;6:1000–1007.
   PubMed Web of Science ®Google Scholar
• Liu C, Kelnar K, Liu B, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011;17:211–215.
   PubMed Web of Science ®Google Scholar
• Lin PC, Chiu YL, Banerjee S, et al. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res. 2013;73:1232–1244.
   PubMed Web of Science ®Google Scholar
• Lynch SM, McKenna MM, Walsh CP, et al. miR-24 regulates CDKN1B/p27 expression in prostate cancer. Prostate. 2016;76:637–648.
   PubMed Web of Science ®Google Scholar
• Cai C, Chen QB, Han ZD, et al. miR-195 inhibits tumor progression by targeting RPS6KB1 in human prostate cancer. Clin Cancer Res. 2015;21:4922–4934.
   PubMed Web of Science ®Google Scholar
• Shi XB, Ma AH, Xue L, et al. miR-124 and androgen receptor signaling inhibitors repress prostate cancer growth by downregulating androgen receptor splice variants, EZH2, and src. Cancer Res. 2015;75:5309–5317.
   PubMed Web of Science ®Google Scholar
• Sacconi A, Biagioni F, Canu V, et al. miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis. 2012;3:e423.
   PubMed Web of Science ®Google Scholar
• Pennati M, Lopergolo A, Profumo V, et al. miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. Biochem Pharmacol. 2014;87:579–597.
   PubMed Web of Science ®Google Scholar
• Hezova R, Kovarikova A, Srovnal J, et al. MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus. Tumour Biol. 2016;37:8007–8018.
   PubMed Web of Science ®Google Scholar
• Li J, Hu K, Gong G, et al. Upregulation of MiR-205 transcriptionally suppresses SMAD4 and PTEN and contributes to human ovarian cancer progression. Sci Rep. 2017;7:41330.
   PubMed Web of Science ®Google Scholar
• Verdoodt B, Neid M, Vogt M, et al. MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer. Int J Oncol. 2013;43:307–314.
   PubMed Web of Science ®Google Scholar
• Bhatnagar N, Li X, Padi SK, et al. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis. 2010;1:e105.
   PubMed Web of Science ®Google Scholar
• Luo G, Wang M, Wu X, et al. Long non-coding RNA MEG3 inhibits cell proliferation and induces apoptosis in prostate cancer. Cell Physiol Biochem. 2015;37:2209–2220.
   PubMed Web of Science ®Google Scholar
• Choi BH, Feng L, Yoon HS. FKBP38 protects Bcl-2 from caspase-dependent degradation. J Biol Chem. 2010;285:9770–9779.
   PubMed Web of Science ®Google Scholar
• Kang CB, Feng L, Chia J, et al. Molecular characterization of FK-506 binding protein 38 and its potential regulatory role on the anti-apoptotic protein Bcl-2. Biochem Biophys Res Commun. 2005;337:30–38.
   PubMed Web of Science ®Google Scholar
• Wang HQ, Nakaya Y, Du Z, et al. Interaction of presenilins with FKBP38 promotes apoptosis by reducing mitochondrial Bcl-2. Hum Mol Genet. 2005;14:1889–1902.
   PubMed Web of Science ®Google Scholar
• Shirane M, Nakayama KI. Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. Nat Cell Biol. 2003;5:28–37.
   PubMed Web of Science ®Google Scholar
• Lin B, Kolluri SK, Lin F, et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell. 2004;116:527–540.
   PubMed Web of Science ®Google Scholar
• Zhang XK. Targeting Nur77 translocation. Expert Opin Ther Targets. 2007;11:69–79.
   PubMed Web of Science ®Google Scholar
• Yu L, Su YS, Zhao J, et al. Repression of NR4A1 by a chromatin modifier promotes docetaxel resistance in PC-3 human prostate cancer cells. FEBS Lett. 2013;587:2542–2551.
   PubMed Web of Science ®Google Scholar
• Leffler H, Carlsson S, Hedlund M, et al. Introduction to galectins. Glycoconj J. 2004;19:433–440.
   PubMed Web of Science ®Google Scholar
• Akahani S, Nangia-Makker P, Inohara H, et al. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 1997;57:5272–5276.
   PubMed Web of Science ®Google Scholar
• Yang H, Lei C, Cheng C, et al. The antiapoptotic effect of galectin-3 in human endometrial cells under the regulation of estrogen and progesterone. Biol Reprod. 2012;87:39.
   PubMed Web of Science ®Google Scholar
• Harazono Y, Nakajima K, Raz A. Why anti-Bcl-2 clinical trials fail: a solution. Cancer Metastasis Rev. 2014;33:285–294.
   PubMed Web of Science ®Google Scholar
• Gleave M, Tolcher A, Miyake H, et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res. 1999;5:2891–2898.
   PubMed Web of Science ®Google Scholar
• Figg WD. The 2005 leon I. Goldberg young investigator award lecture: development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer. Clin Pharmacol Ther. 2006;79:1–8.
   PubMed Web of Science ®Google Scholar
• Paik PK, Rudin CM, Pietanza MC, et al. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer. 2011;74:481–485.
   PubMed Web of Science ®Google Scholar
• Xu H, Krystal GW. Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell lines. Clin Cancer Res. 2010;16:4392–4400.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Hann CL, Garon EB, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012;18:3163–3169.
   PubMed Web of Science ®Google Scholar
• McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992;52:6940–6944.
   PubMed Web of Science ®Google Scholar
• Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol. 1993;143:390–400.
   PubMed Web of Science ®Google Scholar
• Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol. 1996;148:1567–1576.
   PubMed Web of Science ®Google Scholar
• Revelos K, Petraki C, Gregorakis A, et al. Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res. 2005;25:3123–3133.
   PubMed Web of Science ®Google Scholar
• Yancey D, Nelson KC, Baiz D, et al. BAD dephosphorylation and decreased expression of MCL-1 induce rapid apoptosis in prostate cancer cells. PLoS One. 2013;8:e74561.
   PubMed Web of Science ®Google Scholar
• Leslie NR, Kriplani N, Hermida MA, et al. The PTEN protein: cellular localization and post-translational regulation. Biochem Soc Trans. 2016;44:273–278.
   PubMed Web of Science ®Google Scholar
• Wang Y, Romigh T, He X, et al. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines. Hum Mol Genet. 2010;19:4319–4329.
   PubMed Web of Science ®Google Scholar
• Wang Y, Romigh T, He X, et al. Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene. 2011;30:4327–4338.
   PubMed Web of Science ®Google Scholar
• Valiathan RR, Marco M, Leitinger B, et al. Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev. 2012;31:295–321.
   PubMed Web of Science ®Google Scholar
• Pawson T. Tyrosine kinase signalling pathways. Princess Takamatsu Symp. 1994;24:303–322.
   PubMedGoogle Scholar
• Munoz-Moreno L, Bajo AM, Prieto JC, et al. Growth hormone-releasing hormone (GHRH) promotes metastatic phenotypes through EGFR/HER2 transactivation in prostate cancer cells. Mol Cell Endocrinol. 2017;446:59–69.
   PubMed Web of Science ®Google Scholar
• Liu YN, Yin J, Barrett B, et al. Loss of androgen-regulated MicroRNA 1 activates SRC and promotes prostate cancer bone metastasis. Mol Cell Biol. 2015;35:1940–1951.
   PubMed Web of Science ®Google Scholar